PortalPublikationenInterleukin-2 receptor antibody-induced alterations of ciclo...

Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients.

Standard

Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. / Strehlau, J; Pape, L; Offner, G; Nashan, Björn; Ehrich, J H.

in: LANCET, Jahrgang 356, Nr. 9238, 9238, 2000, S. 1327-1328.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Strehlau, J, Pape, L, Offner, G, Nashan, B & Ehrich, JH 2000, 'Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients.', LANCET, Jg. 356, Nr. 9238, 9238, S. 1327-1328. <http://www.ncbi.nlm.nih.gov/pubmed/11073027?dopt=Citation>

APA

Strehlau, J., Pape, L., Offner, G., Nashan, B., & Ehrich, J. H. (2000). Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. LANCET, 356(9238), 1327-1328. [9238]. http://www.ncbi.nlm.nih.gov/pubmed/11073027?dopt=Citation

Vancouver

Strehlau J, Pape L, Offner G, Nashan B, Ehrich JH. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. LANCET. 2000;356(9238):1327-1328. 9238.

Bibtex

@article{27786377576b45b2ada4bf5e6419619e,
title = "Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients.",
abstract = "In a retrospective analysis of paediatric renal-transplant recipients receiving basiliximab, we noted significantly increased blood concentrations of cyclosporin, early cyclosporin toxicity, and a lower dose requirement within the first 10 days compared with controls. As the CD25 saturation fades at days 28-50, cyclosporin concentrations decline and 20% higher doses are required to maintain adequate trough concentrations. We suggest that an interleukin-2 receptor-mediated alteration of the cytochrome P450 system causes this systemic drug interaction and propose that the initial ciclosporin dose should be limited to 400 mg/m2 if used in combination with basiliximab.",
author = "J Strehlau and L Pape and G Offner and Bj{\"o}rn Nashan and Ehrich, {J H}",
year = "2000",
language = "Deutsch",
volume = "356",
pages = "1327--1328",
journal = "LANCET",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9238",

}

RIS

TY - JOUR

T1 - Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients.

AU - Strehlau, J

AU - Pape, L

AU - Offner, G

AU - Nashan, Björn

AU - Ehrich, J H

PY - 2000

Y1 - 2000

N2 - In a retrospective analysis of paediatric renal-transplant recipients receiving basiliximab, we noted significantly increased blood concentrations of cyclosporin, early cyclosporin toxicity, and a lower dose requirement within the first 10 days compared with controls. As the CD25 saturation fades at days 28-50, cyclosporin concentrations decline and 20% higher doses are required to maintain adequate trough concentrations. We suggest that an interleukin-2 receptor-mediated alteration of the cytochrome P450 system causes this systemic drug interaction and propose that the initial ciclosporin dose should be limited to 400 mg/m2 if used in combination with basiliximab.

AB - In a retrospective analysis of paediatric renal-transplant recipients receiving basiliximab, we noted significantly increased blood concentrations of cyclosporin, early cyclosporin toxicity, and a lower dose requirement within the first 10 days compared with controls. As the CD25 saturation fades at days 28-50, cyclosporin concentrations decline and 20% higher doses are required to maintain adequate trough concentrations. We suggest that an interleukin-2 receptor-mediated alteration of the cytochrome P450 system causes this systemic drug interaction and propose that the initial ciclosporin dose should be limited to 400 mg/m2 if used in combination with basiliximab.

M3 - SCORING: Zeitschriftenaufsatz

VL - 356

SP - 1327

EP - 1328

JO - LANCET

JF - LANCET

SN - 0140-6736

IS - 9238

M1 - 9238

ER -